A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia
Participants in this study are at least 70 years of age and have acute myeloid leukemia (AML). Also, the patient has decided against the use of standard intensive treatment for the AML. The purpose of the first part of this study is to confirm the safety and tolerability of giving sapacitabine in alternating cycles with decitabine. The purpose of the second part of this study is to learn which, among several drug options, is more likely to keep the patient's cancer in check as long as possible. This research study will involve approximately 470 subjects at approximately 50 locations. Participation will continue until the disease gets worse or the study closes.
Karen Parrott, 319-353-6347
Pharmacological Ascorbate for the Control of Metastatic and Node-Positive Pancreatic Cancer (PACMAN): A phase II trial
Participants in this research study have been diagnosed with pancreatic cancer and a gemcitabine based chemotherapy has been recommended for treatment. The purpose of this research study is to determine if receiving large doses of ascorbate (vitamin C) improves the response to chemotherapy. Approximately 42 people will take part in this study conducted by investigators at the University of Iowa. Participation in this study will continue as long as the disease is stable and not progressing and the treatment remains gemcitabine as the chemotherapy.
Kellie Bodeker, 319-384-9425
Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888) in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Who can apply: People diagnosed with recurring ovarian, primary peritoneal, or fallopian tube cancer.
Purpose: To determine the appropriate dose of an experimental drug, evaluate side effects when combined with other drugs, and test samples of tumor tissue (if available from a previous surgery or biopsy).
Drugs: ABT-888 (Veliparib), carboplatin and pegylated liposomal doxorubicin (PLD).
Number of participants: 10.
Sharon Stockman, 319-356-2015
The purpose of the study is to evaluate the effectiveness (how much the tumors shrink or disappear) and the safety (side effects and how the drug effects the body) of the drug GPX-150. This study also will determine the greatest tolerated dose, and what happens to GPX-150 in the body and how it is excreted from the body.
Michelle Arnold, 319-356-2778
The purpose of this research study is to look at what will happen if we monitor lung function and symptoms in CF patients more often than we do now. Some of the people in the study will have these followed as they normally do (at their clinic visits). Some people in this study will do lung function tests and fill out questionnaires at home twice a week.
Mary Teresi, PharmD email@example.com
Copyright © 2013 The University of Iowa. All Rights Reserved.